DreamCIS, Inc. (KOSDAQ:223250)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,810.00
+195.00 (5.39%)
At close: Sep 17, 2025
5.39%
Market Cap90.68B
Revenue (ttm)63.74B
Net Income (ttm)6.41B
Shares Out23.80M
EPS (ttm)267.12
PE Ratio14.26
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume725,947
Average Volume647,005
Open3,620.00
Previous Close3,615.00
Day's Range3,595.00 - 3,850.00
52-Week Range2,435.00 - 5,390.00
Beta0.36
RSI54.05
Earnings DateNov 14, 2025

About DreamCIS

DreamCIS, Inc. provides clinical research services in South Korea. It offers clinical development services; biostatic, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd. [Read more]

Industry Commercial Physical and Biological Research
Founded 2000
Employees 354
Stock Exchange KOSDAQ
Ticker Symbol 223250
Full Company Profile

Financial Performance

In 2024, DreamCIS's revenue was 58.65 billion, an increase of 22.59% compared to the previous year's 47.84 billion. Earnings were 5.28 billion, an increase of 41.22%.

Financial Statements

News

There is no news available yet.